Last reviewed · How we verify

NCT04916834

Impact of Severe Acute Respiratory Syndrome (SARS-CoV-2/COVID-19) Related Pneumonia on Lung Function and Structure.

Status unknown Last updated 23 February 2023
What this trial tests

trial in Covid19 in 100 participants. Status unknown.

Timeline
30 August 2020
Primary endpoint
30 November 2023
30 November 2024

Quick facts

Lead sponsorNational Institute for Tuberculosis and Lung Diseases, Poland
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date30 August 2020
Primary completion30 November 2023
Estimated completion30 November 2024
Sites1 location across Poland

Conditions studied

Sponsor

National Institute for Tuberculosis and Lung Diseases, Poland

Who can join

Adults 18 to 100, any sex, with Covid19 or SARS-CoV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective study in a group of patients with COVID-19 pneumonia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other National Institute for Tuberculosis and Lung Diseases, Poland trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04916834.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing